Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases

Enrolling by invitationOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

October 30, 2028

Study Completion Date

December 30, 2028

Conditions
AngiocardiographyHeart FailureIschemic Heart DiseaseAcute Myocardial Infarction (AMI)
Interventions
BIOLOGICAL

Hematological indicators

This project is a retrospective clinical cohort study. STEMI patients undergoing PCI were selected to explore whether hematological indicators such as PIV, SHR, and Lp(a) can improve the accuracy of predicting short-term MACE events in STEMI patients.

BIOLOGICAL

Serological indicators in patients with myocardial infarction

This study selected STEMI patients who underwent PCI and collected their hematological indicators to explore the value of PIV, SHR, Lp(a) and other indicators in improving the accuracy of predicting MACE in STEMI patients in the short term.

BIOLOGICAL

Levels of biomarkers in blood of patients with acute myocardial infarction

Hemoglobin, neutrophil count, lymphocyte count, monocyte count and platelet count values, N-terminal pro-B type natriuretic peptide (NT-proBNP), peak creatine kinase isoenzymes (CK-MB), peak troponin T levels, total cholesterol (TC), fasting blood glucose (FBG), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and blood urine nitrogen, blood creatinine (Cr) and other indicators

Trial Locations (1)

200072

Jing 'an District, Shanghai City, Shanghai

All Listed Sponsors
lead

Ya-Wei Xu

OTHER